|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,066.00 GBX | +0.10% |
|
-2.32% | +13.24% |
| 03-12 | GSK plc Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 11:30 AM | |
| 03-11 | FTSE 100 in the Red as US-Iran War Escalates; UK Commits to IEA Oil Stockpile Release | MT |
| Capitalization | 82.75B 111B 95.84B 86.52B 151B 10,228B 155B 1,023B 408B 4,891B 416B 407B 17,615B | P/E ratio 2026 * |
13x | P/E ratio 2027 * | 12x |
|---|---|---|---|---|---|
| Enterprise value | 94.73B 127B 110B 99.05B 173B 11,709B 178B 1,171B 467B 5,599B 476B 466B 20,166B | EV / Sales 2026 * |
2.8x | EV / Sales 2027 * | 2.6x |
| Free-Float |
94.52% | Yield 2026 * |
3.35% | Yield 2027 * | 3.68% |
Last Transcript: GSK plc
| 1 day | +0.10% | ||
| 1 week | -2.32% | ||
| Current month | -6.13% | ||
| 1 month | -3.91% | ||
| 3 months | +13.45% | ||
| 6 months | +36.14% | ||
| Current year | +13.24% |
| 1 week | 1,987.5 |  | 2,086 |
| 1 month | 1,987.5 | | 2,282 |
| Current year | 1,774 | | 2,282 |
| 1 year | 1,242.5 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 68 | 01/09/2019 |
Charles Bancroft
BRD | Director/Board Member | 66 | 01/05/2020 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -3.10% | 3.15% | 26 M€ | |
| +1.51% | 2.97% | 64 M€ | |
| +5.85% | 2.51% | 8 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.10% | -2.32% | +36.28% | +47.72% | 111B | |
| -0.15% | -0.37% | +21.33% | +217.39% | 895B | |
| -0.30% | -0.94% | +46.50% | +60.27% | 587B | |
| +0.30% | -3.60% | +6.60% | +52.08% | 401B | |
| -1.55% | -8.03% | +11.30% | +25.17% | 345B | |
| -1.16% | -4.00% | +26.17% | +35.39% | 306B | |
| -0.62% | -5.04% | +26.69% | +62.48% | 300B | |
| -0.75% | -3.38% | +22.67% | +7.91% | 289B | |
| +0.59% | -0.43% | +18.42% | +65.73% | 202B | |
| -1.72% | -1.50% | +27.59% | +83.65% | 184B | |
| Average | -0.29% | -2.96% | +24.36% | +65.78% | 362.17B | |
| Weighted average by Cap. | +0.05% | -2.61% | +24.40% | +89.83% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.8B 45.31B 39.15B 35.35B 61.62B 4,178B 63.35B 418B 167B 1,998B 170B 166B 7,196B | 35.42B 47.47B 41.02B 37.03B 64.56B 4,378B 66.38B 438B 175B 2,093B 178B 174B 7,540B |
| Net income | 6.31B 8.46B 7.31B 6.6B 11.5B 780B 11.83B 78.01B 31.1B 373B 31.74B 31.07B 1,344B | 6.8B 9.11B 7.87B 7.11B 12.39B 840B 12.74B 84B 33.48B 402B 34.18B 33.46B 1,447B |
| Net Debt | 11.98B 16.06B 13.88B 12.53B 21.84B 1,481B 22.45B 148B 59.03B 708B 60.26B 58.99B 2,551B | 9.25B 12.4B 10.72B 9.68B 16.87B 1,144B 17.34B 114B 45.59B 547B 46.54B 45.56B 1,970B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/03/26 | 2,066.00 p | +0.10% | 4,933,473 |
| 10/03/26 | 2,064.00 p | +0.88% | 9,407,748 |
| 09/03/26 | 2,046.00 p | +0.39% | 9,596,368 |
| 06/03/26 | 2,038.00 p | -1.83% | 5,642,056 |
| 05/03/26 | 2,076.00 p | -1.84% | 8,767,151 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition